Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial-Reference-Cited by-同舟云学术

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Published:2018-11-08 Issue:11 Volume:15 Page:e1002690
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Landovitz Raphael J.^ORCID,Li Sue,Grinsztejn Beatriz^ORCID,Dawood Halima,Liu Albert Y.^ORCID,Magnus Manya,Hosseinipour Mina C.^ORCID,Panchia Ravindre,Cottle Leslie,Chau Gordon,Richardson Paul,Marzinke Mark A.^ORCID,Hendrix Craig W.^ORCID,Eshleman Susan H.^ORCID,Zhang Yinfeng,Tolley Elizabeth^ORCID,Sugarman Jeremy,Kofron Ryan,Adeyeye Adeola,Burns David,Rinehart Alex R.,Margolis David,Spreen William R.,Cohen Myron S.,McCauley Marybeth,Eron Joseph J.^ORCID

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference29 articles.

1. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men;RM Grant;N Engl J Med,2010

2. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women;JM Baeten;N Engl J Med,2012

3. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana;MC Thigpen;N Engl J Med,2012

4. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection;JM Molina;N Engl J Med,2015

5. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial;S McCormack;Lancet,2016

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peer Influence on Motivation to Use Pre-Exposure Prophylaxis Among Latino Sexual Minority Men in Miami, Florida: A Network Autocorrelation Model;AIDS Patient Care and STDs;2024-08-01

2. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial;The Lancet HIV;2024-08

3. “I Feel Like I Don’t Even Have HIV Anymore”—Facilitators, Barriers, and Experience regarding Use of Long-Acting Injectable Antiretroviral Therapy Among Persons with HIV in North Carolina;AIDS Patient Care and STDs;2024-07-01

4. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine;AIDS;2024-05-30